Emmanuel Mduma, MBBS,MMed Associate Editor Cureus Journal of Medical Science, shared on LinkedIn:
“From HER2 receptor blockade to intelligent drug delivery.
I had the pleasure of presenting ‘Trastuzumab Deruxtecan: Transforming the Treatment Landscape of HER2-Positive and HER2-Low Cancers’ at the scientific meeting organized by the Tanzania Oncology Society (TOS) in collaboration with RENATA PLC.
The meeting brought together oncology professionals to discuss recent advances in HER2-targeted therapy, EGFR inhibition, and immuno-oncology, with a shared goal of improving outcomes for patients through evidence-based, precision cancer care.
The rapid evolution of antibody–drug conjugates, particularly trastuzumab deruxtecan, continues to redefine treatment paradigms across multiple HER2-driven malignancies and highlights the importance of translating emerging clinical evidence into routine oncology practice.”
Other artcles about Tanzania Oncology Society on OncoDaily.
